Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12599085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n=24) received either 2.5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.
Medical subject headings
- Adjuvants, Immunologic
- Capsid
- Capsid Proteins
- Parvoviridae Infections
- Parvovirus
- Polysorbates
- Squalene
- Vaccination
- Viral Vaccines